ENXTPA:ABVXBiotechs
Did Positive Phase 3 Obefazimod Data Just Shift ABIVAX Société Anonyme's (ENXTPA:ABVX) Investment Narrative?
Abivax recently announced new Phase 3 clinical data for obefazimod at the United European Gastroenterology Meeting, showing the therapy achieved clinically meaningful improvements in moderate-to-severely active ulcerative colitis and met its FDA primary endpoints for clinical remission at week 8 in both pivotal ABTECT trials.
Additional safety findings highlighted a favorable profile with no new serious infection or malignancy signals across a large and diverse patient population, including...